ShaikhHKamranAShaikhSet al.Aplastic anemia secondary to propylthiouracil: a rare and life-threatening adverse effect. J Oncol Pharm Pract2018; published online.
2.
AksoyMErdemS. Aplastic anaemia after propylthiouracil. Lancet1968; 1: 1379–1379.
3.
MarteloOJKatimsRBYunisAA. Bone marrow aplasia following propylthiouracil therapy. Report of a case with complete recovery. Arch Intern Med1967; 120: 587–590.
4.
El OstaBHuFSadekRet al.Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol2017; 119: 1–12.
5.
LeroyLLafargeXBlouinLet al.A fatal allo and immune-mediated thrombocytopenia with a PD-L1 inhibitor. Ann Oncol2018; 29: 514–515.
6.
GordonIOWadeTChinKet al.Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother2009; 58: 1351–1353.
7.
ComitoRRBaduLAForcelloN. Nivolumab-induced aplastic anemia: a case report and literature review. J Oncol Pharm Pract2017; Published online.
8.
MichotJMVargaftigJLeducCet al.Immune-related bone marrow failure following anti-PD1 therapy. Eur J Cancer2017; 80: 1–4.
9.
HelgadottirHKisLLjungmanPet al.Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann Oncol2017; 28: 1672–1673.
10.
Du RusquecPSaint-JeanMBrocardAet al.Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother2014; 37: 348–350.
